INTERCURE RANKED NUMBER 136 FASTEST GROWING TECHNOLOGY COMPANY ON THE DELOITTE TECHNOLOGY FAST 500 EMEA 2008.

Attributes 1,227 Percent Revenue Growth to Successful Expansion into Retail Stores

New York, N.Y. – January 12, 2009 InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced that it ranked Number 136 on the Deloitte Technology Fast 500 EMEA 2008, a ranking of the 500 fastest growing technology companies in EMEA. Rankings are based on percentage revenue growth over five years. InterCure grew 1,227 percent during this period.

“Being named as one of the 500 fastest growing technology companies in Europe, Middle East and Africa is a significant recognition for InterCure and indicative of our continued growth and success over the past five years,” said Erez Gavish, president and CEO of InterCure. “Our launch into the retail market allowed us to expand our business and extend our reach, placing RESPeRATE onto the shelves of the neighborhood pharmacies and into the homes of thousands more hypertension sufferers worldwide.”

“Making the Deloitte Technology Fast 500 is commendable in today’s highly competitive technology industry,” said Karel Bakkes, partner in charge of Deloitte’s Technology Fast 500 EMEA program. “We congratulate InterCure on being one of the 500 fastest growing technology companies in the region.”

InterCure previously ranked 170 on 2007 Deloitte Technology Fast 500.

Overall, companies that ranked on the Technology Fast 500 EMEA 2008 program had an average growth rate of 1,297 percent.

About InterCure Ltd. and RESPeRATE
InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42 billion hypertension industry with the world’s first FDA-cleared, OTC blood pressure treatment device, RESPeRATE® (www.resperate.com). In a market where seven out of 10 hypertensives are NOT controlled despite the availability of more than 100 blood pressure medications, RESPeRATE provides an effective adjunctive non-drug therapy with no side effects.

RESPeRATE has gained widespread support of hypertension specialists and has secured regulatory clearance in most key international markets. Ten separate clinical studies have proven the device’s efficacy and safety, and RESPeRATE is now featured in more than 20 popular and professional text books.

With more than 100,000 units sold, thousands of supportive clinicians worldwide and one of the world’s most popular hypertension websites, InterCure is now introducing RESPeRATE into retail pharmacies to increase access to hypertension sufferers.

InterCure has an exciting product pipeline based on its broadly-patented “Device-Guided Breathing” technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia and several other medical conditions.

Advertisements